Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
PMC 10166133
A 2024 study found that people with diabetes taking semaglutide were over four times more likely to develop NAION than those who were not
Pharmaceutics 12 Griffiths OR, Landon J, Coxon RE et al (2020) Inflammatory bowel disease and targeted oral anti-TNFalpha therapy
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
GLP-1RAs attenuate the progression of NASH to hepatocellular carcinoma through enhancement of hepatic metabolic function
US$ 20.44
US$ 21.80
US$ 29.61
US$ 23.19
US$ 22.40
US$ 22.79
US$ 27.93
